Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of bexicaserin in seizures associated with Dravet syndrome
CTR20252345Phase 3Active
- Sponsor
- Longboard Pharmaceuticals
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Dravet syndrome comparing bexicaserin with placebo (2 arms). Primary endpoint: Percent change from baseline in frequency of countable motor seizures during the maintenance treatment period. Started Nov 2025; status: active.
02
Drugs
bexicaserin
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on CTR20252345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252345.